ORION OYJ |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.08 EUR | +0.30% |
|
+6.82% | -0.69% |
| Jun. 03 | Orion Partners with Universities for Biotechnology Project in Finland | MT |
| May. 07 | Orion Corporation Announces Change in Orion Group Executive Management Board as of 31 May 2025 | CI |
| Sales 2024 * | 1.38B 1.5B | Sales 2025 * | 1.45B 1.58B | Capitalization | 5.48B 5.96B |
|---|---|---|---|---|---|
| Net income 2024 * | 242M 263M | Net income 2025 * | 250M 272M | EV / Sales 2024 * | 3.95 x |
| Net cash position 2024 * | 46.22M 50.26M | Net cash position 2025 * | 3.2M 3.48M | EV / Sales 2025 * | 3.77 x |
| P/E ratio 2024 * |
22.7
x | P/E ratio 2025 * |
21.9
x | Employees | 3,698 |
| Yield 2024 * |
4.3% | Yield 2025 * |
4.39% | Free-Float | 89% |
More Fundamentals
* Assessed data
More news
Latest transcript on Orion Oyj
More press releases
More news
| 1 day | +0.23% | ||
| 1 week | +7.15% | ||
| Current month | +4.38% | ||
| 1 month | +8.76% | ||
| 3 months | +9.27% | ||
| 6 months | +8.34% | ||
| Current year | -0.38% |
1 week
36.47
39.16
1 month
35.7139.16
Current year
31.8645.29
1 year
31.8645.29
3 years
31.8655.16
5 years
29.5255.16
10 years
22.5758.50
| Managers | Title | Age | Since |
|---|---|---|---|
Liisa Hurme
CEO | Chief Executive Officer | 57 | 98-12-31 |
| Chief Operating Officer | - | 15-12-31 | |
Outi Vaarala
CTO | Chief Tech/Sci/R&D Officer | 62 | 18-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 63 | 21-03-24 | |
| Director/Board Member | 61 | 17-03-21 | |
| Director/Board Member | 54 | 22-03-22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.96% | 664 M€ | +8.85% | ||
| 2.87% | 473 M€ | +5.94% | ||
| 0.35% | 1,083 M€ | +5.01% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-05 | 39 | +0.08% | 14 932 |
| 24-06-04 | 38.97 | +1.41% | 291,498 |
| 24-06-03 | 38.43 | +2.53% | 287,080 |
| 24-05-31 | 37.48 | +1.38% | 896,225 |
| 24-05-30 | 36.97 | +1.26% | 102,477 |
Delayed Quote Nasdaq Helsinki, June 05, 2024 at 03:17 am EDT
More quotes
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows:
- generic, OTC and biosimilar drugs (43.4%);
- patented prescription products (41.7%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments;
- animal health products (8.7%);
- pharmaceutical ingredients and outsourcing services (6.2%).
Net sales break down primarily by source of revenue between sales of products (86.9%) and royalties (10.4%).
Net sales are distributed geographically as follows: Finland (28%), Scandinavia (12%), Europe (30.8%), North America (14.7%) and other (14.5%).
Sector
Pharmaceuticals
Calendar
2024-08-08
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
38.97
EUR
Average target price
39
EUR
Spread / Average Target
+0.08%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.38% | 5.96B | |
| +42.83% | 750B | |
| +34.11% | 606B | |
| -5.70% | 356B | |
| +18.06% | 326B | |
| +4.63% | 286B | |
| +17.57% | 246B | |
| +10.72% | 213B | |
| -3.52% | 213B | |
| +2.43% | 167B |
- Stock Market
- Equities
- ORNBV Stock
